Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gpASIT+ + DnaK
- Development stage
- Unknown
- Lead developer
- European Medical Solutions
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
gpASIT+ + DnaK is an investigational allergen-specific immunotherapy (AIT) combination developed by BioTech Tools S.A. for the treatment of grass pollen-induced seasonal allergic rhinoconjunctivitis (hay fever). The therapy consists of gpASIT+, a peptide hydrolysate derived from Lolium perenne (ryegrass) pollen, formulated with DnaK, a bacterial heat shock protein 70 (HSP70) that acts as an immunoregulating adjuvant. DnaK is intended to reduce inflammation and enhance the immune system's tolerance to allergens. In Phase IIa clinical trials, the combination demonstrated safety and immunogenicity, characterized by the induction of allergen-specific IgG4 and IgG-associated blocking antibodies, which modulate the allergic response.
- Brand names
- gpASIT+TM
- Other names
- gpASIT+ plus DnaKgpASIT+ with DnaK
02
Targets
MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on gpASIT+ + DnaK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gpASIT+ + DnaK.